The gouty arthritis global market report 2024 from The Business Research Company provides comprehensive market statistics, including global market size, regional shares, competitor market share, detailed segments, trends, and opportunities. This report offers an in-depth analysis of current and future industry scenarios, delivering a complete perspective for thriving in the industrial automation software market.
Gouty Arthritis Market, 2024 report by The Business Research Company offers comprehensive insights into the current state of the market and highlights future growth opportunities.
Market Size –
The gouty arthritis market size has grown strongly in recent years. It will grow from $3.21 billion in 2023 to $3.44 billion in 2024 at a compound annual growth rate (CAGR) of 7.2%. The growth in the historic period can be attributed to the high prevalence of chronic diseases, increased alcohol intake, an increase in the elderly population, growing acceptance of enhanced regeneration therapies, and rising healthcare expenditure.
The gouty arthritis market size is expected to see strong growth in the next few years. It will grow to $4.57 billion in 2028 at a compound annual growth rate (CAGR) of 7.3%. The growth in the forecast period can be attributed to improvements in healthcare infrastructure, increased obesity, an increased incidence of gout, and increasing awareness among people. Major trends in the forecast period include growing demand for effective treatment options, regenerative therapies, technological advancements, product launches, and regulatory approvals.
Order your report now for swift delivery @
https://www.thebusinessresearchcompany.com/report/gouty-arthritis-global-market-report
Scope Of Gouty Arthritis Market
The Business Research Company’s reports encompass a wide range of information, including:
1. Market Size (Historic and Forecast): Analysis of the market’s historical performance and projections for future growth.
2. Drivers: Examination of the key factors propelling market growth.
3. Trends: Identification of emerging trends and patterns shaping the market landscape.
4. Key Segments: Breakdown of the market into its primary segments and their respective performance.
5. Focus Regions and Geographies: Insight into the most critical regions and geographical areas influencing the market.
6. Macro Economic Factors: Assessment of broader economic elements impacting the market.
Gouty Arthritis Market Overview
Market Drivers –
The increasing prevalence of obesity is expected to propel the growth of the gouty arthritis market going forward. Obesity is a medical disorder characterized by the buildup of extra body fat to the point where it threatens an individual’s health and is frequently measured using the body mass index (BMI). The rate of obesity is rising due to increased consumption of high-calorie, processed foods and sedentary lifestyles. Obesity contributes to gouty arthritis by increasing the production of uric acid and reducing the body’s ability to excrete it, leading to the accumulation of uric acid crystals in the joints. Additionally, excess body weight places more stress on joints, exacerbating the inflammation and pain associated with gout. For instance, in March 2022, according to the World Health Organization, a Switzerland-based specialized United Nations agency responsible for worldwide public health, around 1 billion individuals, comprising 650 million adults, 340 million teenagers, and 39 million children, were classified as obese, with this figure continuing to rise. Furthermore, the projections indicate that by 2025, approximately 167 million adults and children will suffer health consequences due to excess weight. Therefore, the increasing prevalence of obesity is driving the growth of the gouty arthritis market.
Market Trends –
Major companies operating in the gouty arthritis market are increasing their efforts to develop novel products, such as cortrophin gel, to provide more effective and targeted therapies for managing the condition. Cortrophin gel, also known as repository corticotropin injection, is a purified form of the adrenocorticotropic hormone (ACTH). It is used to treat various inflammatory and autoimmune conditions, including gouty arthritis. For instance, in October 2023, ANI Pharmaceuticals, a US-based pharmaceutical company, received approval from the Food and Drug Administration for a new 1-mL vial size of Purified Cortrophin Gel. This product is intended for the adjunctive treatment of certain patients experiencing acute gouty arthritis flares. Cortrophin Gel is currently the only FDA-approved adrenocorticotropic hormone (ACTH) therapy indicated for treating appropriate patients with acute gouty arthritis flares.
The gouty arthritis market covered in this report is segmented –
1) By Type: Acute Gouty Arthritis, Chronic Gouty Arthritis
2) By Treatment: Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Pain Reliever, Corticosteroids, Xanthine Oxidase Inhibitors, Uricosurics, Others Treatments
3) By Diagnosis: Joint Fluid Test, Blood Test, X-Ray Imaging, Ultrasound, Dual Energy Computed Tomography (CT) Scan, Other Diagnosis
4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Others Distribution Channels
5) By End-Users: Hospitals, Specialty Clinics, Other End-Users
Get an inside scoop of the gouty arthritis market, Request now for Sample Report @
https://www.thebusinessresearchcompany.com/sample.aspx?id=16070&type=smp
Regional Insights –
North America was the largest region in the gouty arthritis market in 2023. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the gouty arthritis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Key Companies –
Major companies operating in the gouty arthritis market are Pfizer Inc., Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Bristol Myers Squibb, AstraZeneca plc, Novartis International AG, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Gilead Sciences Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Biogen Inc., Vertex Pharmaceuticals Incorporated, UCB S.A., Boehringer Ingelheim International GmbH, Sun Pharmaceutical Industries Ltd., Horizon Therapeutics plc, Dr. Reddy’s Laboratories Ltd., Amneal Pharmaceuticals Inc., Lupin Pharmaceuticals Inc.
Table of Contents
1. Executive Summary
2. Gouty Arthritis Market Report Structure
3. Gouty Arthritis Market Trends And Strategies
4. Gouty Arthritis Market – Macro Economic Scenario
5. Global Gouty Arthritis Market Size and Growth
.
.
.
32. Global Gouty Arthritis Market Competitive Benchmarking
33. Global Gouty Arthritis Market Competitive Dashboard
34. Key Mergers And Acquisitions In The Gouty Arthritis Market
35. Gouty Arthritis Market Future Outlook and Potential Analysis
36. Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
